Diabetes pharmacotherapy aims to achieve glycemic control near physiologic levels to prevent microvascular and macrovascular complications of chronic hyperglycemia. Diabetes mellitus encompasses type 1 diabetes (absolute insulin deficiency), type 2 diabetes (insulin resistance with relative insulin deficiency), and other specific types. The treatment landscape has expanded substantially, with newer agents offering cardiovascular and renal protective benefits beyond glucose lowering.
What Is Diabetes Pharmacotherapy?
Glycemic targets are individualized based on patient age, disease duration, comorbidities, and risk of hypoglycemia. Hemoglobin A1c is the primary measure of glycemic control over the preceding 2 to 3 months, with most guidelines targeting less than 7 percent for non-pregnant adults. Type 1 diabetes requires lifelong insulin therapy, while type 2 diabetes management begins with lifestyle modification and metformin, with sequential addition of other agents as needed.
Drug Classes and Mechanisms
Insulin preparations are classified by onset and duration: rapid-acting (lispro, aspart, glulisine), short-acting (regular insulin), intermediate-acting (NPH), long-acting (glargine, detemir, degludec), and premixed formulations. Insulin binds to insulin receptors, promoting cellular glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis. Metformin activates AMP kinase, reducing hepatic glucose production and improving insulin sensitivity with minimal hypoglycemia risk. Sulfonylureas (glipizide, glyburide, glimepiride) stimulate pancreatic beta-cell insulin secretion by blocking ATP-sensitive potassium channels. Meglitinides (repaglinide, nateglinide) have a similar mechanism but shorter duration, taken with meals. Thiazolidinediones (pioglitazone) activate PPAR-gamma, improving insulin sensitivity in adipose tissue, muscle, and liver. DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) prevent degradation of incretin hormones GLP-1 and GIP, enhancing glucose-dependent insulin secretion. GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) activate GLP-1 receptors, promoting insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting weight loss. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block renal glucose reabsorption, causing glucosuria and modest HbA1c reduction with substantial cardiovascular and renal benefits. Alpha-glucosidase inhibitors (acarbose) delay carbohydrate absorption in the gut.
Therapeutic Uses
Metformin is first-line for type 2 diabetes. For patients with established cardiovascular disease, chronic kidney disease, or heart failure, SGLT2 inhibitors or GLP-1 receptor agonists with demonstrated cardiovascular benefit are recommended as part of initial therapy. Sulfonylureas and insulin remain important options when cost is a concern. Type 1 diabetes requires basal-bolus insulin regimens or continuous subcutaneous insulin infusion.
Adverse Effects
Metformin causes gastrointestinal intolerance and rarely lactic acidosis in patients with severe renal impairment. Sulfonylureas cause weight gain and hypoglycemia. Thiazolidinediones are associated with fluid retention, heart failure exacerbation, and fracture risk. GLP-1 receptor agonists cause nausea, vomiting, and diarrhea, with rare pancreatitis. SGLT2 inhibitors increase genitourinary infection risk and rarely cause euglycemic diabetic ketoacidosis.
Key Clinical Considerations
Hypoglycemia is the most important limiting factor in diabetes management, particularly with insulin and sulfonylureas. Patient education on self-monitoring of blood glucose, sick-day management, and recognizing hypoglycemia symptoms is essential. Renal function guides drug selection and dosing, particularly for metformin and SGLT2 inhibitors. Weight effects differ substantially between classes and influence treatment selection.
Conclusion
Diabetes pharmacotherapy has evolved from a focus on glucose lowering alone to a comprehensive approach addressing cardiovascular and renal risk. Metformin remains foundational for type 2 diabetes, while GLP-1 receptor agonists and SGLT2 inhibitors offer additional benefits beyond glycemic control. Insulin therapy is essential for type 1 diabetes and advanced type 2 diabetes.
